| | Univariate | Multivariate |
|---|
| HR (95% CI) | p-value | HR (95% CI) | p-value |
|---|
| Treatment intervala |
| Group 1 | 1 (reference) | | | |
| Group 2 | 1.113 (0.680–1.822) | 0.670 | | |
| Age |
| < 65 yr | 1 (reference) | | | |
| ≥ 65 yr | 0.679 (0.271–1.701) | 0.409 | | |
| CA-125 |
| < 40 U/mL | 1 (reference) | | 1 (reference) | |
| ≥ 40 U/mL | 1.976 (1.187–3.287) | 0.009 | 1.620 (0.954–2.749) | 0.074 |
| Histology |
| Serous | 1 (reference) | | | |
| Non-serous | 1.081 (0.597–1.956) | 0.798 | | |
| Surgery |
| Laparoscopy | 1 (reference) | | | |
| Laparotomy | 1.657 (0.900–3.051) | 0.105 | | |
| ASA scoreb |
| 1 | 1 (reference) | | | |
| 2, 3 | 0.808 (0.458–1.426) | 0.462 | | |
| Residual diseasec |
| R0 | 1 (reference) | | 1 (reference) | |
| R1, R2 | 2.366 (1.384–4.046) | 0.002 | 2.031 (1.161–3.554) | 0.013 |
| Platinum free interval |
| 6-12mo | 1 (reference) | | 1 (reference) | |
| over 12mo | 0.509 (0.276–0.940) | 0.031 | 0.582 (0.309–1.095) | 0.093 |
| Recurrence no. |
| 1st recur | 1 (reference) | | | |
| 2nd recur | 0.967 (0.416–2.247) | 0.938 | | |
- aEnrolled patients were divided into two groups; Group1 (treatment interval ≤ 10 days) and Group2 (treatment interval > 10 days)
- bASA score, American Society of Anaesthesiologists score
- cThe level of residual disease after SCS was divided into no gross (R0), 1–9 mm (R1), and equal to or more than 10 mm residual disease (R2)
